SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebiuss Q3 results sparked a sharp, volatile reaction: despite a strong reported quarter, traders focused on higher planned capital spending and delayed capacity and revenue milestones, raising concerns about funding needs and potential dilution. Bulls argued that strong AI-cloud demand, customer prepayments and the longer-term outlook supported the business, while some also blamed broader pressure from Nvidia-related headlines.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Reports of Nvidia board discussions about potentially removing Jensen Huang, amid allegations involving a company executive and a suspected Chinese spy, have driven concern about leadership continuity and national-security scrutiny. Traders are divided between fearing a CEO transition and further fallout, and viewing the selloff as a buying opportunity because Nvidias AI business remains strong.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas reported Q3 revenue beat and raised outlook are driving attention, with traders highlighting its large backlog and earlier profitability target. Bulls are calling for a short squeeze, while skeptics point to weaker margins, a wider adjusted EBITDA loss, and falling cash reserves.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines stronger-than-expected Q3 results, including positive free cash flow and a record backlog, are driving attention, with traders also citing the companys revenue outlook. Many see the report as a potential turnaround, while skeptics point to ongoing losses, dilution concerns and the stocks history of giving back gains.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Traders are focused on the FDAs Nov. 22 decision on Capricors deramiocel for Duchenne muscular dystrophy, with the application now centered on preserving upper-limb function. The recent rally has fueled approval and short-squeeze speculation, while skeptics point to the earlier advisory committee vote and warn that the outcome remains uncertain.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

A strong quarterly report and raised outlook sparked a sharp rally, but traders then focused on reports of turmoil around Nvidia CEO Jensen Huang and whether it could affect CoreWeaves ties to Nvidia. Bulls say AI demand and contracted backlog remain intact, while bears point to heavy debt costs and potential dilution as risks that the earnings momentum may not resolve.

Boost Run, Inc. is a provider of scalable cloud infrastructure purpose-built for enterprise AI and high-performance computing workloads. The platform delivers GPU compute, CPU nodes, managed Kubernetes orchestration, and shared storage through an intuitive management console and a robust API layer, enabling organizations to provision and scale resources across thousands of nodes in minutes. The company was founded on September 5, 2025 and is headquartered in Northbrook, IL.

Boost Run Inc. - Ordinary Shares - Class A

Boost Run Inc.

BRUN is drawing attention after Q3 results showed sharply higher year-over-year revenue but missed analyst expectations. Traders are split between optimism about its AI-cloud backlog and project financing and concern that contracts have yet to translate into sustained revenue and profitability.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSCIs confirmed decision to remove Strategy from its indexes is driving concern about passive-fund selling and weaker institutional demand; traders also point to Bitcoins decline as pressure on the stock. Bearish voices expect further downside, while bulls argue the index news is priced in and Bitcoins direction matters more.

ERock, Inc. operates, designs, and installs distributed generation power systems. The firm primarily serves data centers, utilities, commercial and industrial businesses. The company was founded on 2006 and is headquartered in Houston, TX.

ERock Inc. - Ordinary Shares - Class A

ERocks quarterly results are drawing attention, with traders highlighting a return to profitability, strong revenue growth, and reaffirmed full-year guidance alongside a larger backlog tied to AI data-center power demand. Many see the report as bullish and speculate that high short interest could amplify a move, while others remain cautious about execution and volatile price action.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedixs quarterly results drew attention, but managements decision to defer 2027 DefenCath revenue guidance amid uncertainty around CMS reimbursement, utilization and Medicare Advantage is the central concern. Traders are weighing that unclear outlook against stronger-than-expected results and the Heron acquisitions potential to diversify revenue, with reactions split between optimism about the broader portfolio and concern about DefenCaths reimbursement outlook.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Devon Q3 Earnings Outpace Estimates on Higher Output, Revenues Miss

DVN's Q3 earnings beat estimates as the Coterra merger drives higher production, but revenues fall short despite strong growth in oil and gas sales.

Plains All American Q3 Earnings Lag Estimates, Sales Increase Y/Y

PAA Q3 results lag estimates despite a 31.1% sales increase, while higher pipeline volumes and the Cactus III acquisition boost EBITDA.

Occidental Petroleum to Release Q3 Earnings: What's in the Cards?

OXY gears up for Q3 earnings, with strong domestic production, drilling efficiencies and lower interest costs likely to have supported profitability.

Sempra's Q3 Earnings Outpace Estimates, Revenues Increase Y/Y

SRE's Q3 earnings surge 26.1%, beating estimates as stronger Oncor equity earnings and infrastructure performance offset revenue weakness.

National Fuel Gas Q4 Earnings Outpace Estimates, Revenues Increase Y/Y

NFG beats Q4 earnings estimates as revenues rise year over year despite higher operating costs and lower natural gas production.

Oneok Inc. (OKE) is a Top-Ranked Value Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Ormat Technologies Q3 Earnings and Revenues Beat Estimates

ORA beats Q3 2026 earnings and revenue estimates, fueled by surging Energy Storage sales, and raises its full-year revenue and EBITDA outlook.

Oneok Inc. (OKE) is a Top-Ranked Momentum Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Energy Transfer Q3 Earnings Miss Estimates Despite Record Gas Volumes

ET's Q3 earnings miss estimates despite record gas volumes, revenues surge 85.9%, and 2026 adjusted EBITDA guidance is raised to $19.7-$19.9 billion.

Cash Dividend On The Way From ONEOK (OKE)

Looking at the universe of stocks we cover at Dividend Channel, on 11/2/26, ONEOK Inc (Symbol: OKE) will trade ex-dividend, for its quarterly dividend of $1.07, payable on 11/16/26. As a percentage of OKE's recent stock price of $97.47, this dividend works out to approximately...

• Reported GAAP EPS of $2.13 up 42.95% YoY
• Reported revenue of $12.46B up 44.26% YoY
• ONEOK increased 2026 net income guidance to $4.09B to $4.27B and adjusted EBITDA guidance to $8.5B to $8.6B; capital expenditure guidance is approximately $3.5B.

ONEOKs NGL adjusted EBITDA declined year over year, net income included a $336M one-time noncash tax benefit, and operations depend on third-party producers, gathering systems, refineries and pipelines.

ONEOKs NGL raw feed throughput increased 6%, Refined Products and Crude adjusted EBITDA increased, and the Brazos acquisition was completed with approximately $50M expected in adjusted EBITDA net of transaction costs.

ONEOK, Inc. operates as a holding company, which engages in gathering, processing, fractionation, transportation, storage, and marine export services. It transports natural gas, natural gas liquids, refined crude oil products, and crude oil to domestic and international energy demand, contributes to energy security, and provides energy solutions. The company was founded on August 13, 2026 and is headquartered in Oklahoma, OK.

Oneok Inc

Why Did AMLX, IOVA, OKE Stocks Hit 52-Week Highs Today? 

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>Amylyx stock rose to a three-year high after avexitide cut hypoglycemic events by 55% in Phase 3 testing.&nbsp;&nbsp;</li><li>Iovance’s Amtagvi is gaining commercial traction, with Q2 revenue rising 66% year over year to $99.3 million.</li><li>Morgan Stanley increased&nbsp;ONEOK’s price target to $105 from $103.&nbsp;</li></ul><p>Amylyx Pharmaceuticals (AMLX), Iovance Biotherapeutics (IOVA) and ONEOK (OKE) climbed to fresh 52-week highs on Tuesday. The moves followed developments that reduced uncertainty around each company's outlook and prompted analysts to reassess their valuations.</p><p>Amylyx Pharmaceuticals stock surged 63%, while ONEOK gained nearly 2%. Iovance Biotherapeutics pared its gains to end Tuesday’s trading session 0.99% lower.&nbsp;</p><h2 class="st-heading-2">Amylyx's Clinical Boost</h2><p><a href="https://stocktwits.com/symbol/AMLX">Amylyx stock</a> reached a three-year high of $35.39 after&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/amlx-stock-clocks-best-day-ever-after-positive-trial-data-launches-350-m-offering/cZYcnMtRJjw">reporting</a> encouraging Phase 3 results for avexitide, its treatment candidate for post-bariatric hypoglycemia (PBH). The drug&nbsp;slashed combined Level 2 and Level 3 hypoglycemic events by 55% versus placebo. The trial also met all secondary endpoints, showing significant reductions across multiple measures of hypoglycemia.&nbsp;&nbsp;</p><p>Amylyx plans to submit an FDA New Drug Application by the end of 2026. The drug already has FDA Breakthrough Therapy and Orphan Drug designations. The company also proposed raising $350 million through a public stock offering, giving it additional resources as it prepares for potential commercialization.&nbsp;</p><p>Stifel responded by more than doubling its price target to $45 from $21 while retaining a ‘Buy’ rating. On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory.&nbsp;</p><h2 class="st-heading-2">Mizuho Raises Iovance Target On Impressive Q2 Performance&nbsp;</h2><p><a href="https://stocktwits.com/symbol/IOVA">Iovance Biotherapeutics stock</a> hit a 52-week high of $7.31, driven by post-fiscal second-quarter earnings momentum, expanding margin profiles, and fresh price-target hikes from Wall Street analysts like Mizuho.&nbsp;</p><p>The stock is also in focus as its flagship tumor-infiltrating lymphocyte (TIL) therapy, Amtagvi, transitions from initial market launch to a scalable, high-margin commercial engine. Iovance’s Q2 revenue of $99.3 million surged 66% year-on-year as demand increased for Amtagvi. Gross margin reached 56% after manufacturing shifted fully to the company's internal facility.</p><p>On Tuesday, Mizuho raised its IOVA target to $11 from $10 and kept an Outperform rating, citing stronger adoption and a broader network of treatment centers. Retail sentiment around the stock remained in ‘bullish’ territory.&nbsp;</p><h2 class="st-heading-2">ONEOK Rides AI Energy Demand&nbsp;</h2><p><a href="https://stocktwits.com/symbol/OKE">ONEOK stock</a> hit a 52-week high of $97.90 fueled by a strong Q2 earnings beat, higher 2026 guidance and a deal to supply natural gas to a 1-gigawatt power plant serving AI data centers. The company raised its 2026 adjusted EBITDA guidance midpoint by $250 million to $8.35 billion and EPS guidance to $5.68.&nbsp;</p><p>Morgan Stanley raised its price target for Oneok to $105 from $103 while keeping a ‘neutral’ rating on the stock.&nbsp;Retail sentiment around the stock remained in ‘bullish’ territory.&nbsp;</p><p>So far this year, OKE, IOVA and AMLX stocks have gained between 32% and 190%.&nbsp;</p><p>Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ondas-stock-heads-for-monthly-gain-why-this-analyst-still-sees-150-upside/cZYcRFQRJSN">Ondas Stock Heads For Monthly Gain: Why This Analyst Still Sees 150% Upside?</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

ProKidney (PROK) is developing rilparencel, an autologous cellular therapy aimed at slowing kidney function decline in patients with chronic kidney disease/ Photo credit: Getty Images

Investors responded to clinical progress, improving commercial performance and new growth opportunities.

Why Did AMLX, IOVA, OKE Stocks Hit 52-Week Highs Today?

Investors responded to clinical progress, improving commercial performance and new growth opportunities.


Amylyx Pharmaceuticals Inc

Iovance Biotherapeutics Inc

Oneok Inc.

Track OKE stock price, charts, news and real-time market activity on Stocktwits. Join the OKE message board to follow investor discussions, retail trader sentiment, bullish and bearish signals around Oneok Inc stock.

OKE Stock Price Today - Oneok Inc News, Charts, Retail Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	$1.49	--	--	N/A
Q3 '26	$1.50	$2.13	41.60%	BEAT
Q2 '26	$1.46	$1.53	5.10%	BEAT
Q1 '26	$1.30	$1.23	-5.10%	MISSED
Q4 '25	$1.50	$1.55	3.32%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

OKE Earnings

Latest Earnings Results: Q3 '26

Historical Earnings